Overview

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Status:
Not yet recruiting
Trial end date:
2023-09-10
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborator:
Gedeon Richter Plc.